Status:
RECRUITING
Exploring Cancer Evolution, Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC
Lead Sponsor:
Sun Yat-sen University
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
To investigate genomic architecture, cancer evolution and their relationship with clinical outcomes in EGFR-mutant NSCLC.
Detailed Description
EGFR mutations are detected in about 50% of East Asian NSCLC and 10% of Western NSCLC. EGFR-mutant NSCLC harbors distinct genomic architecture including high ITH, early diversification, genome instabi...
Eligibility Criteria
Inclusion
- Aged 18 years or older
- Histologically or cytologically confirmed non-small-cell lung cancer
- ECOG PS=0-2
- EGFR mutations confirmed by tissue or peripheral blood
- Can provide tumor tissue samples (fresh or archived)
- The subject should have good compliance, who would participate in the research voluntarily, and sign the informed consent
Exclusion
- History of other malignancies within 5 years (excluding basal cell carcinoma of the skin or other carcinoma in situ that has been resected).
- Unable to provide sufficient tumor tissue for analysis.
- Subjects with active, unstable systemic diseases, such as active infection, uncontrolled hypertension, heart failure (NYHA class \>= II), unstable angina pectoris, acute coronary syndrome, severe arrythmia, severe liver, kidney or metabolic diseases, HIV infection.
- Subjects who are deemed unable to comply with the study requirements or complete the study.
Key Trial Info
Start Date :
August 10 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2030
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT05997719
Start Date
August 10 2023
End Date
December 31 2030
Last Update
October 24 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sun Yat-sen University Cancer Center
Guanzhou, China, 510060